Product Description.:
ALTABAX is the topical antibacterial for impetigo that targets Staphylococcus aureus (methicillin-susceptible isolates only) and Streptococcus pyogenes in your patients.
Important Safety Information
ALTABAX is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes.
The most common drug-related adverse reaction was application site irritation (1.4% of patients).
References:
1. Data on file ABX107-01, GlaxoSmithKline.
2. Kosowska-Shick K, Clark C, Credito K, et al. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother. 200650:765-769.
3. Koning S, van der Wouden JC, Chosidow O, et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol. 2008158:1077-1082.
4. Rittenhouse S, Biswas S, Broskey J, et al. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob Agents Chemother. 200650:3882-3885.
5. Yan K, Madden L, Choudhry AE, Voigt CS, Copeland RA, Gontarek RR. Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes. Antimicrob Agents Chemother. 200650:3875-3881.
6. Bactroban Ointment (mupirocin ointment), 2% [package insert]. Research Triangle Park, NC: GlaxoSmithKline 2001